1-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]吡咯烷 | 852227-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]吡咯烷
• 中文别名: 4-(1-吡咯烷基)苯硼酸频哪醇酯；4-苯硼酸频哪吡咯烷；吡咯烷,1-[4-(4,4,5,5-四甲基-1,3,2-二氧杂环己硼烷-2-基)苯基]；1-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)苯基)吡咯烷；1-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)苯基)吡咯烷
• 英文名称: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine
• 英文别名: 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine
• CAS: 852227-90-8
• 化学式: C₁₆H₂₄BNO₂
• 分子量: 273.183
• InChiKey: DWJNNJSONWFVBT-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C
• 沸点：
  396.0±25.0 °C(Predicted)
• 密度：
  1.05

计算性质

• 辛醇/水分配系数(LogP)：
  2.59
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Pyrrolidinophenylboronic acid, pinacol ester
Product Name:
Synonyms: 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Pyrrolidinophenylboronic acid, pinacol ester
Ingredient name:
CAS number: 852227-90-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H24BNO2
Molecular weight: 273.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]吡咯烷 在 Cu(OTf)2(py)4 、 N,N-二甲基甲酰胺 作用下， 以 乙腈 为溶剂， 反应 0.33h， 生成 1-(4-[18F]fluorophenyl)pyrrolidine
  参考文献：
  名称：

  消除杂环正电子发射断层扫描放射性配体的铜介导的 18F-氟化

  摘要：

  用氟 18 (18F) 标记的分子用于正电子发射断层扫描，以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展，但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法，使用铜介导的 18F 氟化芳基硼试剂与 18F 氟化物作为模型反应。该方法基于一项研究，该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-氟化效率，以及超过 50 种（杂）芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。

  DOI：

  10.1021/jacs.7b03131
• 作为产物：
  描述：

  1-苯基吡咯烷 在 三(五氟苯基)硼烷 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 49.0h， 生成 1-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]吡咯烷
  参考文献：
  名称：

  富电子芳烃的催化Friedel–Crafts CH硼氢化反应：增加的烯烃加速速率

  摘要：

  在富电子芳族化合物与儿茶酚硼烷的亲电CHH硼化反应中，亲电硼的催化生成是由各种Lewis和Brønsted酸对BH键的杂化作用引发的，它仅形成硼离子。配体解离后，相应的硼离子在苯胺衍生物以及含氮杂环上进行区域选择性亲电芳香取代。使用B（C 6 F 5）3来优化催化作用作为引发剂，并且在不添加外部碱或二氢受体的情况下进行。为了确保这些Friedel-Crafts型反应的有效转换，通常需要高于80°C的温度。机理实验表明，释放氢的硼/硼离子的再生是决定速率的。这一发现最终导致人们发现，添加烯烃后，催化CHH硼化可以首次在室温下进行。

  DOI：

  10.1002/anie.201611536

文献信息

• NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
  申请人：BOOKSER BRETT C.

  公开号：US20100081643A1

  公开（公告）日：2010-04-01

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，并且在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病方面非常有用。本发明的化合物在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面非常有用。
• NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES
  申请人：APGAR James M.

  公开号：US20150284411A1

  公开（公告）日：2015-10-08

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可能在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病中有用。本发明的化合物可能在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面有用。
• [EN] NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'INDOLE UTILES EN TANT QU'AGENTS ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014139388A1

  公开（公告）日：2014-09-18

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可能在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病中有用。本发明的化合物可能在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面有用。
• Room-Temperature Practical Copper-Catalyzed Amination of Aryl Iodides
  作者：Christopher Deldaele、Gwilherm Evano

  DOI：10.1002/cctc.201501375

  日期：2016.4.6

  An efficient and highly practical procedure is reported for the Ullmann–Goldberg‐type copper‐catalyzed amination of aryl iodides. By using a combination of copper iodide and proline in the presence of an excess of an amine, a wide range of aryl iodides can be readily aminated at room temperature. The reaction proceeds well regardless of the electronic properties of the starting aryl iodide and the

  据报道，Ullmann–Goldberg型铜催化芳基碘化物的胺化反应是一种有效且高度实用的程序。通过在过量胺的存在下使用碘化铜和脯氨酸的组合，可以在室温下容易地胺化各种各样的芳基碘。无论起始碘代芳基化物的电子性质如何，反应都进行得很好，并且在大多数情况下不需要通过柱色谱法纯化就可以得到胺化产物。由于其效率和反应条件的温和性，该胺化反应还可扩展至在室温下胺化复杂的芳基碘化物。
• [EN] COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS EN TANT QUE MODULATEURS DE LA SIGNALISATION TLR
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2020198368A1

  公开（公告）日：2020-10-01

  The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

  本发明公开涉及化合物、包含此类化合物的药物组合物，以及此类化合物在治疗炎症性疾病和与炎症信号传导过程相关的某些神经障碍的方法或药物中的用途，所述神经障碍包括但不限于错误折叠的蛋白质。